Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Doctil Plus
- Development stage
- Unknown
- Lead developer
- Maks Drug
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Doctil Plus is a combination antibiotic containing cefuroxime, a second-generation cephalosporin, and clavulanic acid, a beta-lactamase inhibitor. Developed and manufactured by Maks Drug Limited in Bangladesh, it is used to treat a variety of bacterial infections including respiratory tract infections (pharyngitis, sinusitis, bronchitis, pneumonia), urinary tract infections, skin and soft tissue infections, and typhoid fever. Cefuroxime works by inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanic acid protects cefuroxime from degradation by beta-lactamase enzymes produced by resistant bacteria, thereby extending its spectrum of activity.
- Brand names
- Doctil Plus
- Other names
- cefuroxime + clavulanic acid
02
Targets
PBP (Penicillin-binding protein family)β-lactamase
Beyond the preview
Go deeper on Doctil Plus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Doctil Plus.